CIPLA CINACALCET cinacalcet (as hydrochloride) 30 mg tablet bottle

Ülke: Avustralya

Dil: İngilizce

Kaynak: Department of Health (Therapeutic Goods Administration)

Aktif bileşen:

cinacalcet hydrochloride, Quantity: 33.064 mg (Equivalent: cinacalcet, Qty 30 mg)

Mevcut itibaren:

Cipla Australia Pty Ltd

Farmasötik formu:

Tablet, film coated

Kompozisyon:

Excipient Ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake

Uygulama yolu:

Oral

Paketteki üniteler:

28's

Reçete türü:

(S4) Prescription Only Medicine

Terapötik endikasyonlar:

Cipla Cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (HPT) in patients with end stage renal disease, receiving dialysis (see section 5.1 Pharmacodynamic properties, Clinical trials). Cipla Cinacalcet should be used as adjunctive therapy.,Cipla Cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,Cipla Cinacalcet may be used to treat the biochemical manifestations of primary HPT in patients for whom parathyroidectomy is not a treatment option.

Ürün özeti:

Visual Identification: Light green coloured, oval shaped, biconvex film-coated tablets, debossed with "CL" on one side and "410" on other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

2023-02-07